ProCE Banner Activity

SGLT2 Inhibitor Use in People With Heart Failure

Clinical Thought

If we could design the ideal drug for preventing and treating heart failure, it would look a lot like an SGLT2 inhibitor. Read my take on why we should be using SGLT2 inhibitors in people with heart failure across the spectrum of left ventricular ejection fraction to improve functionality and outcomes.

Released: August 23, 2024

Expiration: August 22, 2025

Share

Faculty

Javed Butler

Javed Butler, MD, MPH, MBA

President of the Baylor Scott and White Research Institute
Senior Vice President for the Baylor Scott and White Health
Maxwell A. and Gayle H. Clampitt Endowed Chair
Dallas, Texas
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Disclosure

Primary Author

Javed Butler, MD, MPH, MBA

President of the Baylor Scott and White Research Institute
Senior Vice President for the Baylor Scott and White Health
Maxwell A. and Gayle H. Clampitt Endowed Chair
Dallas, Texas
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi

Javed Butler, MD, MPH, MBA: consultant/advisor/speaker: Abbott, American Regent, Amgen Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Janssen, Levator, Lexicon, Lilly, LivaNova, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Roche, Salamandra, Salubris, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, Zoll.